Annals of Surgical Oncology

, Volume 16, Issue 4, pp 993–1000 | Cite as

Hyperthermic Intraperitoneal Chemotherapy After Extensive Cytoreductive Surgery in Patients with Primary Advanced Epithelial Ovarian Cancer: Interim Analysis of a Phase II Study

  • Myong Cheol Lim
  • Sokbom Kang
  • Jaeho Choi
  • Yong Jung Song
  • Sohee Park
  • Sang-Soo Seo
  • Sang-Yoon Park
Gynecologic Oncology



The objective of the current study was to evaluate the toxicities and treatment response of intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.


Intraoperative HIPEC (cisplatin 75 mg/m2, 41.5°C, 90 min) was performed in 30 patients with residual tumor of <1 cm after cytoreductive surgery between January 2007 and February 2008. All the patients received adjuvant chemotherapy with combination platinum and taxane. Adverse events and responses to primary treatment were evaluated and scored as follows: grade I, observation; grade II, medical treatment; grade III, intervention; and grade IV, reoperation or admission to the intensive care unit.


No deaths or grade IV morbidities were observed. One hundred seven adverse events were identified in 30 patients (grade I, 40; grade II, 46; grade III, 21). The most common adverse events affected the hematologic system (n = 26), followed by the gastrointestinal system (n  = 23). Most adverse events were anemias requiring transfusion and nausea/vomiting requiring medication. Twenty-eight patients (93%) experienced complete remission, and two patients (7%) had progressive disease.


HIPEC after extensive cytoreductive surgery for ovarian cancer is a procedure with acceptable morbidity that patients can tolerate. More follow-up is needed to determine the effect of HIPEC on survival.


  1. 1.
    National Cancer Institute. NCI clinical announcement: intraperitoneal chemotherapy for ovarian cancer. 2006. Available at: Accessed January 15, 2009.
  2. 2.
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.PubMedCrossRefGoogle Scholar
  3. 3.
    Park S. Postoperative adjuvant intraperitoneal chemotherapy in patients with advanced ovarian cancer. Cancer Res Treat. 2006;38:36s–7s.Google Scholar
  4. 4.
    Vergote I, Amant F, Leunen K, et al. Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view. Oncologist. 2008;13:410–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100:27–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Sugarbaker PH. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia. 2007;23:431–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Helm CW, Bristow RE, Kusamura S, Baratti D, Deraco M. Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer. J Surg Oncol. 2008;98:283–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Yan TD, Zappa L, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. J Surg Oncol. 2007;96:102–12.PubMedCrossRefGoogle Scholar
  10. 10.
    Gonzalez-Bayon L, Gonzalez-Moreno S, Ortega-Perez G. Safety considerations for operating room personnel during hyperthermic intraoperative intraperitoneal chemotherapy perfusion. Eur J Surg Oncol. 2006;32:619–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92:1534–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Eisenhauer EL, D’Angelica MI, Abu-Rustum NR, et al. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. Gynecol Oncol. 2006;103:871–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635–44.PubMedCrossRefGoogle Scholar
  14. 14.
    Yan TD, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma—a prospective study of 70 consecutive cases. Ann Surg Oncol. 2007;14:515–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Capone A, Valle M, Proietti F, et al. Postoperative infections in cytoreductive surgery with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis. J Surg Oncol. 2007;96:507–13.PubMedCrossRefGoogle Scholar
  16. 16.
    Kim S, Kim Y, Kim J. New paradigm of intraperitoneal chemotherapy in ovarian carcinoma. Korean J Gynecol Oncol. 2006;17:1–14.Google Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Myong Cheol Lim
    • 1
    • 2
  • Sokbom Kang
    • 1
  • Jaeho Choi
    • 1
    • 3
  • Yong Jung Song
    • 1
  • Sohee Park
    • 4
  • Sang-Soo Seo
    • 1
  • Sang-Yoon Park
    • 1
  1. 1.Center for Uterine Cancer, Research Institute and HospitalNational Cancer CenterGoyang-si, Gyeonggi-doKorea
  2. 2.Department of Obstetrics and GynecologyKyung Hee UniversitySeoulKorea
  3. 3.Department of Obstetrics and Gynecology, Dagin Medical CenterBundang Jaesaeng HospitalGyeonggi-doKorea
  4. 4.Center for Clinical Trial, Research Institute and HospitalNational Cancer CenterGyeonggi-doKorea

Personalised recommendations